Key terms
About VNRX
VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluids. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest VNRX news
Mar 19
4:31pm ET
VolitionRx names Dr Andrew Retter as Chief Medical Officer
Jan 03
7:23am ET
Analysts Offer Insights on Healthcare Companies: Medios AG (OtherMEDOF), Universal Health (UHS) and VolitionRX (VNRX)
Jan 02
1:34pm ET
VolitionRx milestone payment ‘important step forward,’ says EF Hutton
Jan 02
1:32pm ET
VolitionRx announces receipt of $13M in milestone payments from Heska
VNRX Financials
Key terms
Ad Feedback
VNRX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
VNRX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range